PRI 100
Alternative Names: PRI-100Latest Information Update: 10 Oct 2022
At a glance
- Originator Priavoid
- Class Antiparkinsonians; Peptides
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 22 Sep 2022 PRI 100 is available for licensing as of 22 Sep 2022. https://priavoid.com/partnering-and-investors/
- 13 Sep 2022 Preclinical trials in Parkinson's disease in Germany (unspecified route) (Priavoid pipeline, September 2022)